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ABSTRACT. Aldose reductase is an enzyme that catalyzes one of the steps in the sorbitol (polyol) pathway that is responsible 
for fructose formation from glucose. In diabetes, aldose reductase activity increases as the glucose concentration increases. 
The purpose of this research was to identify and develop the use of artemisinin as an anti-diabetic candidate through in 
silico studies, including reverse docking, receptor analysis, molecular docking, drug scan, absorption, and distributions and 
toxicity prediction of artemisinin. Based on the results, we conclude that artemisinin can be used as an anti-diabetic candidate 
through inhibition of aldose reductase. 
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INTRODUCTION 
Diabetes is a chronic disease that occurs when the 
pancreas does not produce enough insulin or when 
the body is unable to use insulin effectively. In 2014, 
8.5% of adults aged 18 years and over suffered from 
diabetes. In 2016, diabetes was the direct cause of 
around 1.6 million deaths. Diabetes is classified as 
type 1 diabetes (insulin-dependent) and type 2 
diabetes (non-insulin-dependent) (World Health 
Organization, 2016). Fidarestat is an aldose 
reductase inhibitor studied in the treatment of diabetes 
neuropathy (Steuber, Heine, Podjarny, & Klebe, 
2008). Aldose reductase is an enzyme that is normally 
present in many other parts of the body, and it 
catalyzes one of the steps in the sorbitol(polyol) 
pathway that is responsible for fructose formation from 
glucose. Aldose reductase activity increases as the 
glucose concentration increases in individuals with 
diabetes in the tissues that are not insulin sensitive 
(Várkonyi, 2008). 
Artemisinin is a sesquiterpene lactone compound 
that consists of three isoprene units that are bound to 
cyclic esters. The (+) artemisinin has been used as an 
antimalarial drug by the Chinese since 168 BC. This 
compound was first isolated in 1972 from the 
Qinghao plant (Artemisia annua L.) by Chinese 
chemists, and it has a peroxide bridge that is the main 
proponent of antimalarial drug activity (Li, 2012). The 
need for malaria medicine in the world is very high, 
while the artemisinin produced from the Qinghao 
plant cannot be sufficient. This situation prompted 
several researchers to make synthetic antimalarial 
drugs based on the structure of artemisinin 
(Aderibigbe, 2017; Muangphrom, Seki, Fukushima, & 
Muranaka, 2016; Walsh, Coughlan, Heneghan, 
Gaynor, & Bell, 2017). 
Aside from being an antimalarial drug (Das, 2015; 
Guo, 2016), artemisinin has also been investigated as 
an antituberculosis (Zheng et al., 2017); anticancer 
(Li, Li, Wu, Wang, & Yu, 2016; Slezakova, 2017; 
Wong et al., 2017), and anti-diabetic drug (Helal, 
Abou-Aouf, Khattab, & Zoair, 2014). 
Drug repurposing is a strategy for identifying new 
uses for approved or investigational drugs that are 
outside the scope of the original medical indication. 
Successful drug repositioning occurred in 2015 with 
the identification and use of aspirin for colorectal 
cancer, in 2014 with the identification of ketoconazole 
for Cushing syndrome, and in 2007 with the use of 
Raloxifene for breast cancer (Pushpakom et al., 2018). 
Apart from experimentation, with computational 
chemical methods, the structure of a new drug 
compound with new activity can be predicted. One of 
the computational methods used in the design and 
development of new drugs is the docking method 
(Kitchen, Decornez, Furr, & Bajorath, 2004). The 
molecular docking approach can be used to model 
interactions between small molecules and proteins at 
the atomic level, which allows for the characterization 
of the behavior of small molecules at the target 
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protein-binding site and explanation of the important 
biochemical processes (Kharkar, Warrier, & Gaud, 
2014). The docking procedure involves two principal 
steps: prediction of the ligand conformation and the 
position and orientation on the sites (commonly 
referred to as poses) and binding affinity assessments. 
The docking method can be used to study interactions 
between one drug and one target receptor (docking) 
as well as to study one drug with many target receptors 
(reverse docking). Some research has been done 
either by docking or reverse docking (Liu et al., 2010; 
Ruswanto et al., 2018). 
The purpose of this research was to identify and 
develop the use of artemisinin as an anti-diabetic 
candidate through in silico studies, including the 
identification of receptor targets (reverse docking), 
receptor analysis, molecular docking, drug scans, 
absorption and distribution, and toxicity prediction of 
artemisinin.  
 
EXPERIMENTAL SECTION 
Ligand Preparation 
The artemisinin structure is already available in the 
PubChem database (https://pubchem.ncbi.nlm.nih. 
gov/compound/68827), and then the artemisinin 
structure was done protonation and conformational by 
MarvinSketch (Purnomo, 2013). 
Target Receptor Identification by Inverse Docking 
The  artemisinin  structure  that  has  been  made 
in  the  preparation  process  with the file format 
".mol2" was uploaded on the website http://lilab-
ecust.cn/pharmmapper/index.html. Submit the file, 
then download the results of the work on Get Result by 
entering the Job ID code given after uploading the file 
(Liu et al., 2010). 
Docking Validation 
Docking was executed using Autodock version 4.2 
software. The artemisinin structure was docked to 
obtain the lowest binding energy with the protein 
target using the Lamarckian genetic algorithm (LGA) 
AutoDock calculation method on grid box x, y, and z 
respectively 22, 18, and 22, spacing 0.375 Angstroms 
and grid box center position 17,789; – 8,179 and 16. 
Data analysis was performed using the root-mean-
square deviation (RMSD). The docking method was 
said to be proper if the RMSD was less than or equal 
to 2 Å. If the RMSD was greater than 2 Å, it means that 
the method could not be trusted (Adelin, 2013). 
Target Receptor Analysis 
Target receptor analysis was performed by looking 
at the aldose reductase (code PDB: 2PDY) profile on 
the following website: http://www.ebi.ac.uk/pdbsum/. 
By entering the 2PDY code, the profile data from the 
target receptor appeared. This analysis was carried 
out at target receptors that were validated in the 
docking validation process (De Beer, Berka, Thornton, 
& Laskowski, 2014). 
 
Docking and Interaction Visualization 
The docking process was done using Autodock 
version 4.2 software. Then, the test compound was 
docked at the receptor-binding site following the grid 
box that was used in the validation. The results 
obtained from this docking process were in the form 
of the binding affinity of the compounds or ligands. 
Furthermore, using LigPlot software, the interaction 
between the ligand and the active site of the receptor 
could be seen (Wallace, Laskowski, & Thornton, 
1996). 
Lipinski’s Rule of Five (Drug Scan) 
Drug scan analysis was carried out on artemisinin 
compounds and if a chemical compound with a 
certain pharmacological or biological activity has 
chemical properties and physical properties that would 
make it a likely orally active drug in humans (Lipinski's 
rule of five) using MarvinSketch software (Lipinski, 
Lombardo, Dominy, & Feeney, 1997). 
The observation of the drug was performed by 
observing the rule of good medicine (Lipinski's rule of 
five) and oral bioavailability of ligand. The parameters 
for Lipinski’s rule of five (RO5) were the following: 
molecular weight < 500 g/mol, lipophilicity < 5, 
donor hydrogen bond < 5, acceptor hydrogen bond 
< 10, and refractory molar among 40 and 130 
(Athar, Lone, & Jha, 2017; Choy, 2011). 
The Absorption, Distribution and Toxicity Prediction 
The PreADMET program was accessed at 
http://Preadmet.bmdrc.org/. The structure of each 
compound was converted to mol files (*.mol2). The 
program automatically calculated the predicted 
absorption for Caco-2, human intestinal absorption 
(HIA), and bound plasma receptors (Rozano, Zawawi, 
Ahmad, & Jaganath, 2017), while the identification of 
toxicity parameters was Ames test, carcinogenic in 
mice, and inhibition on hERG. 
 
RESULTS AND DISCUSSION 
The in-silico study of artemisinin compounds was 
performed in several stages, including docking, 
prediction of absorption-distribution, prediction of 
toxicity, and screening of similar drug compounds 
(drug scans) to test the use of these compounds as 
anti-diabetic candidates. 
Ligand Preparation Results 
Ligand preparation was carried out before the in-
silico test so that the ligand of the artemisinin 
compound was ready for treatment in the subsequent 
procedure. The first preparation was done by drawing 
the structure using MarvinSketch. 
Target Identification Results 
Tuberculosis receptors that could have potential as 
artemisinin compounds were identified with a web 
server-based program, PharmMapper (http://lilab-
ecust.cn/pharmmapper/), designed to identify 
potential target receptor candidates for small 
molecules. Identification was carried out by 
examination using a pharmacophore mapping 
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approach that was also used to determine the 
interaction between pharmacophore compounds with 
receptors (Wang et al., 2017). 
In this study, the prepared compound was 
uploaded to the PharmMapper webserver to analyze 
potential receptor targets. Several target receptor 
candidates with the potential to fit the fit score and z’-
score parameters were obtained.  The identification 
results for the top 10 receptor targets are given in 
Table 1. From the results, it can be seen tuhat the top 
10 receptor codes are selected receptors. The highest 
fit score was found for the receptor with the code 
2PDY, which had a z'-score of 2.22103 and a fit score 
of 3.699. The more positive of the z'-score value, it 
means more significant the target receptor is towards 
the test compound, while the more negative the z'-
score value, it means the target receptor maybe not 
enough significant (Wang et al., 2016). 
The pharmacophore features of artemisinin can be 
seen in Table 2 and Figure 2, the four identified aldose 
reductase receptors have the same number of 
hydrophobic molecules, which causes the formation of 
hydrophobic bonds between molecules. This 
hydrophobic bond forms between the non-polar 
region of the drug molecules and the non-polar region 
of the biological receptor, whereas hydrogen and 
hydrophobic bonds affect the conformational stability 
that occurs between artemisinin compounds and 
receptor targets. 
 
  
           (a)      (b) 
Figure 1. Artemisinin structure. (a) 2D structure and (b) 3D structure that was optimized with 
ChemOffice 2004 software. 
 
Table 1.  PharmMapper Results of artemisinin compounds. 
Rank PDB ID. Target Name 
Number of 
Features 
Fit Score 
Normalized 
Fit Score 
Z’score 
1 
2 
3 
4 
5 
 
6 
7 
8 
9 
10 
2PDY 
1PWM 
2PDW 
2PD9 
2PEO 
 
1LNM 
1RCJ 
2NW4 
1T87 
3D9Z 
Aldose reductase 
Aldose reductase 
Aldose reductase 
Aldose reductase 
3-phosphoinositide-
dependent protein kinase 1 
Bilin-binding protein 
Beta-lactamase SHV-1 
Androgen receptor 
Camphor 5-monooxygenase  
Carbonic anhydrase 2 
4 
4 
4 
4 
4 
 
4 
4 
4 
4 
4 
3.699 
3.657 
3.645 
3.596 
3.498 
 
3.496 
3.491 
3.368 
3.244 
3.219 
0.9248 
0.9142 
0.9114 
0.8989 
0.8744 
 
0.8739 
0.8728 
0.8421 
0.8110 
0.8046 
2.22103 
2.06726 
1.97695 
1.76382 
1.22248 
 
0.59119 
0.42665 
0.79402 
-0.1831 
0.10992 
 
 
Table 2. Pharmacophore features of artemisinin in the top five receptors. 
 No. Target receptor 
Number of pharmacophore features 
Hydrophobic Positive Negative Donor Acceptor Aromatic 
1 Aldose reductase 2 0 0 0 2 0 
2 Aldose reductase 2 0 0 0 2 0 
3 Aldose reductase 2 0 0 0 2 0 
4 Aldose reductase 2 0 0 0 2 0 
5 
3-phosphoinositide-
Dependent receptor 
kinase 1 
3 0 0 0 1 0 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
 
(e) 
Figure 2. Pharmacophore model features of artemisinin with receptor targets. (a) Aldose reductase-2PDY, (b) 
aldose reductase-1PWN, (c) aldose reductase-2PDW, (d) aldose reductase-2PD9, and (e) 3-phosphoinositide-
dependent receptor kinase 2-PE0. 
 
 
(a) 
 
(b) 
 
(c) 
Figure 3. The pharmacophore models of artemisinin in aldose reductase: (a) molecule and pharmacophore, (b) 
models of the molecule and molecular features, and (c) pharmacophore model and molecular features. The 
following colors correspond to features of the pharmacophore: hydrophobic, cyan; positive (cations), blue; 
negative (anions), red; hydrogen bond donor, green; and hydrogen bond acceptor, magenta 
 
Docking Validation 
This step involved re-docking of fidarestat from the 
crystal structure (2PDY) to the active site using the 
same procedure as the docking procedure used in this 
study, which was performed by Autodock. Afterward, 
the comparison between the fidarestat obtained from 
the redocking and the fidarestat on the PDB file 
resulted in RMSD. As we know, fidarestat is a drug 
used for the treatment of neuropathic diabetes through 
the aldose reductase mechanism (Steuber et al., 
2008). An RMSD value of 0.48 Å was obtained and 
the overlaid structures can be seen in Figure 4.  
The RMSD was 0.48 Å, indicating that the 
conformation of the re-docking results was similar to 
the results of the x-ray crystallography. This RMSD also 
proves that the docking method was valid for docking 
of the test compound. 
Target Receptor Analysis  
The best receptor target (2PDY) of artemisinin that 
has been identified from PharmMapper was analyzed 
using the PDBSum server (http://www.ebi.ac.uk/ 
thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl? 
pdbcode=index.html). 
The analyzed receptor target was the best-
sequenced target, aldose reductase (2PDY), analyzed 
by the Ramachandran Plot parameter to determine the 
quality of the receptor structure being modeled. The 
plot that describes the amino acid residues in the 
receptor structure is called a Ramachandran Plot. Each 
receptor amino acid has one angle phi (φ) and psi (ψ) 
so that each amino acid residue can be described as 
a plot/coordinate. The quality of the receptor structure 
can be assessed based on a plot of non-glycine 
residues located in the disallowed region. A receptor 
has poor (very unstable) structural quality if the non-
glycine residues in the disallowed region number more 
than 15%. In addition, receptor analysis is also seen 
from the active site of the target receptor, which is an 
area where the substrate molecules bind and undergo 
reaction chemistry. The active site consists of residues 
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that form a temporary bond with the substrate (binding 
site) and residues that catalyze a reaction with the 
substrate (Jorgensen, 1991). 
Based on the Ramachandran plot analysis, the 
aldose reductase receptor (2PDY) shows the number 
of good amino acids, which is larger than or alike to 
91.7% in the greatest favored region so it can be 
assumed that the structure of receptor has excellent 
property (Lakshmi et al., 2014). A clearer result can be 
viewed in Figure 5. 
Another way to observe the constancy of the 
receptor structure is to look at the plot of non-glycine 
residues that are located in disallowed regions. The 
protein structure is good if the number of residues in 
disallowed regions is less than 0.8% (Halkides, 2013; 
Lakshmi et al., 2014). 
 
 
Figure 4. The overlaid image of the crystal structure of fidarestat (yellow) and the re-docking results (red) 
 
 
Figure 5. Ramachandran plot statistics. 
 
 
Figure 6. The Interaction of fidarestat with aldose reductase (2PDY code by PDBsum analysis). 
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Table 3. The free energy binding (G) and constant of inhibition (Ki) 
Compounds G (kcal/mol) Ki 
Artemisinin –8.75 383.73 nM 
Fidarestat –7.23 5.04 µM 
 
Based on the Ramachandran plot observations 
(Figure 5), the receptor structure (2PDY) has a good 
property, this can be noticed from the residual plot 
found in the disallowed regions [X, X] is a smaller 
amount than 0.8%, which is 0.0%.  
On the active site of the aldose reductase (2PDY) 
target receptor with fidarestat, five hydrogen bonds 
with Tyr 48 amino acid residues, 2 on His 110, Trp 
111 and Leu 300 and five hydrophobic interactions 
with Trp 20, Phe 122, Trp 79, Cys 298, and Trp 219. 
(Figure 6). 
Docking Results 
Docking was carried out using Autodock version 
4.2 software. The artemisinin compounds were 
docked to realize the smallest binding energy using the 
LGA AutoDock calculation method, tGA, and SA 
Monte Carlo on grid box x, y, and z respectively 22, 
18, and 22, spacing 0.375 Angstroms and grid box 
center position 17.789; –8.179 and 16.9. From the 
re-docking results, the RMSD value is 0.48 Å and is 
illustrated by the overlay structure between the natural 
ligands and re-docking results, as shown in Figure 4. 
During the docking procedure, the water at the 
receptors is eliminated first because if the clusters of 
compounds and receptors are surrounded by water 
molecules, the surrounding water molecules will 
combine. This phenomenon results in an escalation in 
entropy and a decrease in free energy, which stabilizes 
the drug-receptor complex. Through this procedure, 
hydrogen is also combined, which is important for the 
interaction between the compound and the receptor. 
The docking results of artemisinin against aldose 
reductase (2PDY) were related with fidarestat, which 
are compounds that have been found to work on 
aldose reductase receptors.  
From the results of docking in Table 3, it can be 
seen that the artemisinin has a lower free energy 
binding (ΔG) than a comparative compound 
(Fidarestat). Therefore, the artemisinin can be 
expected to have better activity than fidarestat as an 
anti-diabetic candidate, which acts on the aldose 
reductase receptor. If the free energy binding was 
lower, it means the drug-receptor interaction was 
better and more stable. In adding to the free energy 
binding value, in Table 3 the value of the constant of 
inhibition (Ki) can also be seen. The enzyme 
inhibition constant (Ki), also known as the inhibitor 
dissociation constant, is an equilibrium constant of a 
reversible inhibitor for complexion with its target 
enzyme. Unless otherwise specified, all inhibitors 
described hereafter are reversible inhibitors. Ki is 
associated with thermodynamic parameters in ΔG = 
RT ln(Ki), where ΔG, R, and T are the absolute binding 
free energy, the gas constant, and the absolute 
temperature, respectively (Darras et al., 2017). From 
the reaction equilibrium among the receptor and the 
compound, the lesser the Ki value the more the 
reaction equilibrium leans to favor the formation of 
receptor–compound complexes. The Ki of artemisinin 
was lesser than fidarestat, so it can be predicted that 
the artemisinin has inhibition on the aldose reductase 
receptor better than fidarestat. 
Besides, from the docking results, visualization of 
the 2D interactions between artemisinin and fidarestat 
compounds with aldose reductase receptors can be 
seen, as shown below. 
 
 
(a) 
 
(b) 
 
Figure 7. The visualization of the 2D interaction between artemisinin (a) and fidarestat (b) with aldose reductase 
receptors by the docking method. 
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From Figure 7, it can be seen that the interactions 
between artemisinin compounds and aldose reductase 
are only hydrophobic interactions, namely with Cys 
298, Leu 300, Trp 111, Tyr 209, His 110, Tyr 48, Trp 
79, Trp 20, Phe 122, Trp 219, and Val 47 (11 
interactions). The interaction between fidarestat and 
aldose reductase involves two interactions of hydrogen 
with Leu 300 (2.Å) and Asn 160 (2.91 Å) and eight 
hydrophobic interactions with Cys 298, Val 47 Trp 219 
Trp 20, Trp 111, Tyr 209, His 110, and Tyr 48. 
 
Drug Scan Results 
From the results through the webserver at 
http://www.scfbio-iitd.res.in/software/drugdesign/lip- 
inski.jsp# anchortag, the artemisinin fulfilled the 
Lipinski's RO5, which has a log P < 5, a molecular 
weight of < 500 g/mol, hydrogen bond acceptor 
<10, hydrogen bond donor < 5, and refractory molar 
between 40 and 130 (Lipinski et al., 1997). The weight 
of molecular is correlated to the distribution of the 
drug. If the molecular weight is small, it will have a 
small molecular size. Therefore, it will make it easier 
for the drug to breach the biological membrane. The 
drug scan of results can be seen in Table 4. 
The partition coefficient (log P) is related to 
lipophilicity, which is the chemical dissolving capacity 
in fat, oil, and non-polar solvents. The drug must be 
lipophilicity enough to breach the lipid bilayer, but it 
should not be too lipophilicity, affecting the drug to not 
breach back out of the membrane, which will source 
the drug to be toxic because it keeps on elongated in 
the body. 
The number of donors and acceptors of hydrogen 
bonds is related to the biological activity of a drug, 
which can affect the chemical-physical properties such 
as boiling point, melting point, solubility in water, 
capability in forming chelate, and acidity, whereas 
Refractory molar is correlated to the polarisation total 
of the drug, which is very reliant on the index of 
refractive, pressure and temperature. This polarisation 
is related to the shape of molecular and relative mass, 
which is usually the greater number of electrons, the 
easier it is to experience polarisation. 
 
Table 4. Drug scan test results. 
Parameters Result 
Molecular weight 282 g/mol 
Lipophilicity (Log P) 2.394 
Hydrogen bond donor 0 
Hydrogen bond acceptor 5 
Refractory molar 68.047 
 
From the scan of drug results presented in Table 4, 
it is recognized that artemisinin has fulfilled the 
requirements  of  Lipinski's  rules,  so  it can be 
expected  that  artemisinin  has  good  permeability 
and is easily absorbed. 
Absorption, Distribution and Toxicity Prediction Results 
Based on the prediction results of PreADMET, it was 
known that artemisinin compounds have permeability 
in the medium category, which was seen from the 
Caco2 cell parameter value of 25.2822 nm/sec which 
is in the range of 4–70 nm/sec. This Caco2 cell 
parameter also describes the active and passive 
diffusion transport of a drug molecule. Then, from the 
parameters of HIA, the synthesized compounds fall 
into the good category (range of 70–100%), with a 
value of 93.5899%, so that it could be predicted that 
the compound can reach the target site optimally. The 
HIA parameter was used to predict the percentage of 
absorption of a drug in the human intestine, whereas, 
from the parameters of protein plasma binding (PPB), 
artemisinin compounds have chemical strongly bonds 
with plasma receptors, with a %PPB of 93.805%, 
where the category of %PPB is chemicals strongly 
bound (if %PPB> 90%) and chemicals weakly bound 
(if %PPB<90%). The %PPB value indicated the part of 
the drug that was bound to the plasma receptor that 
cannot diffuse across the cell membrane so that it 
could not interact with the target site. 
In the further test, the toxicity prediction through 
http://Preadmet.bmdrc.org/ by the Ames test, the 
artemisinin was predicted to be mutagenic and 
carcinogenic in both mice showed negative/non-
carcinogenic. Besides, it could be seen from the 
inhibition on hERG that it could be explained that the 
artemisinin has a low risk. Therefore, it could be 
concluded that artemisinin could be safely used as 
medicines (Schmitz, 2008). 
 
CONCLUSION 
From the reverse docking and molecular docking 
study, it can be concluded that artemisinin could be 
used as an anti-diabetic candidate through the aldose 
reductase mechanism. Also, drug scans, receptor 
analysis, adsorption, distribution, and toxicity 
prediction studies were performed. In the future, 
stability interactions between artemisinin and aldose 
reduction inhibitors can be further studied through 
molecular dynamics. 
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